Centre for Targeted Protein Degradation
The Centre for Targeted Protein Degradation (CeTPD) is bolstering the University of Dundee’s world-leading position in a field that is revolutionising drug discovery.
Targeted protein degradation
Targeted protein degradation co-opts the cell’s natural disposal systems to remove disease-causing proteins and is applicable to diverse therapeutic areas including oncology, dermatology, immunology, neuroscience and respiratory diseases.
This entirely new approach is revolutionising drug discovery by making the treatment of diseases previously thought to be undruggable a reality.
CeTPD is part of the University’s School of Life Sciences, one of the UK’s top institutions for research into biological sciences.
Dundee researchers and teams led by Professor Alessio Ciulli have previously revealed fundamental insights into the working of the degrader molecules that they have designed and that are used across the globe. Collaborations with pharma companies Boehringer Ingelheim and Almirall amongst others are helping to advance the field, while the biopharmaceutical company Amphista Therapeutics is a University of Dundee spin-out of the Ciulli Lab.
Our new translational research centre will build on this established excellence to innovate groundbreaking science and accelerate translation by developing and inspiring the next generation of scientists and leaders.
Professor Alessio Ciulli
The University of Dundee is to partner with global biopharmaceutical company Almirall to develop new treatments for severe skin diseases with high level of unmet medical need.
Amphista Therapeutics, a University of Dundee spinout company, has announced a near-£40 million investment that will further its work to develop new drugs for a range of diseases.
A new translational research centre will bolster the University of Dundee’s world-leading position in a field that is revolutionising drug discovery, while helping to facilitate the development of high growth companies and create skilled jobs.
The expansion of an exemplary industry-academia collaboration will see the University of Dundee intensify its efforts to develop new medicines that target and destroy key cancer-causing proteins, which have previously been regarded as undruggable
Scientists at the University of Dundee have developed a new technology that provides a greater understanding into the biology of ‘undruggable’ diseases.
Researchers from the University of Dundee and Promega Corporation have shown how a “three-headed hydra” significantly improves efficacy in a field of chemical biology that is revolutionising drug discovery.
University of Dundee spinout Amphista Therapeutics will work with global biopharmaceutical companies as part of strategic collaborations potentially worth more than $2 billion.
The University of Dundee and Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents, will partner to commercialise technology developed at Dundee that enhances the understanding of undruggable diseases.